[1] L. R. Martin, S. L. Williams, K. B. Haskard, and M. R. Dimatteo, “The challenge of patient adherence,” Ther Clin Risk Manag, vol. 1, no. 3, pp. 189–199, Sep. 2005.
[2] A. O. Iuga and M. J. McGuire, “Adherence and health care costs,” Risk Manag Healthc Policy, vol. 7, pp. 35–44, Feb. 2014, doi: 10.2147/RMHP.S19801.
[3] R. M. Benjamin, “Medication Adherence: Helping Patients Take Their Medicines As Directed,” Public Health Rep, vol. 127, no. 1, pp. 2–3, 2012.
[4] New England Healthcare Institute, “Thinking outside the pillbox: a system-wide approach to improving patient medication adherence for chronic disease.,” NEHI Research Brief, Aug. 2009, Accessed: Aug. 19, 2020. [Online]. Available: https://www.nehi.net/writable/publication_files/file/pa_issue_brief_final.pdf.
[5] R. McCarthy, “The price you pay for the drug not taken,” Bus Health, vol. 16, no. 10, pp. 27–28, 30, 32–33, Oct. 1998.
[6] N. M. Siafakas and D. Bouros, “Consequences of poor compliance in chronic respiratory diseases,” European Respiratory Journal, vol. 5, no. 1, pp. 134–136, Jan. 1992.
[7] W. J. Burman, D. L. Cohn, C. A. Rietmeijer, F. N. Judson, R. R. Reves, and J. A. Sbarbaro, “Noncompliance With Directly Observed Therapy for Tuberculosis: Epidemiology and Effect on the Outcome of Treatment,” Chest, vol. 111, no. 5, pp. 1168–1173, May 1997, doi: 10.1378/chest.111.5.1168.
[8] S. Kane, D. Huo, J. Aikens, and S. Hanauer, “Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis,” Am. J. Med., vol. 114, no. 1, pp. 39–43, Jan. 2003, doi: 10.1016/s0002-9343(02)01383-9.
[9] K. S. Ingersoll and J. Cohen, “The impact of medication regimen factors on adherence to chronic treatment: a review of literature,” J Behav Med, vol. 31, no. 3, pp. 213–224, Jun. 2008, doi: 10.1007/s10865-007-9147-y.
[10] A. G. Bulloch, C. E. Adair, and S. B. Patten, “Forgetfulness: A Role in Noncompliance with Antidepressant Treatment,” Can J Psychiatry, vol. 51, no. 11, pp. 719–722, Oct. 2006, doi: 10.1177/070674370605101110.
[11] G. S. Gaude, J. Hattiholi, and A. Chaudhury, “Role of health education and self-action plan in improving the drug compliance in bronchial asthma,” J Family Med Prim Care, vol. 3, no. 1, pp. 33–38, Jan. 2014, doi: 10.4103/2249-4863.130269.
[12] J. R. Ickovics and A. W. Meisler, “Adherence in AIDS clinical trials: a framework for clinical research and clinical care,” J Clin Epidemiol, vol. 50, no. 4, pp. 385–391, Apr. 1997, doi: 10.1016/s0895-4356(97)00041-3.
[13] C. Penn, J. Watermeyer, and M. Evans, “Why don’t patients take their drugs? The role of communication, context and culture in patient adherence and the work of the pharmacist in HIV/AIDS,” Patient Educ Couns, vol. 83, no. 3, pp. 310–318, Jun. 2011, doi: 10.1016/j.pec.2011.02.018.
[14] W. H. Shrank et al., “The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions,” Arch. Intern. Med., vol. 166, no. 3, pp. 332–337, Feb. 2006, doi: 10.1001/archinte.166.3.332.
[15] K. F. Foreman et al., “Impact of a text messaging pilot program on patient medication adherence,” Clin Ther, vol. 34, no. 5, pp. 1084–1091, May 2012, doi: 10.1016/j.clinthera.2012.04.007.
[16] M. R. DiMatteo, “Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research,” Med Care, vol. 42, no. 3, pp. 200–209, Mar. 2004, doi: 10.1097/01.mlr.0000114908.90348.f9.
[17] A. J. Claxton, J. Cramer, and C. Pierce, “A systematic review of the associations between dose regimens and medication compliance,” Clin Ther, vol. 23, no. 8, pp. 1296–1310, Aug. 2001, doi: 10.1016/s0149-2918(01)80109-0.
[18] M. R. DiMatteo, “Evidence-based strategies to foster adherence and improve patient outcomes,” JAAPA, vol. 17, no. 11, pp. 18–21, Nov. 2004.
[19] H. Mochizuki, Y. Nanjo, and H. Takahashi, “Better adherence to a transdermal tulobuterol patch than inhaled salmeterol in elderly chronic obstructive pulmonary disease patients,” Geriatr Gerontol Int, vol. 13, no. 2, pp. 398–404, Apr. 2013, doi: 10.1111/j.1447-0594.2012.00916.x.
[20] P. G. Conaghan, M. Serpell, P. McSkimming, R. Junor, and S. Dickerson, “Satisfaction, Adherence and Health-Related Quality of Life with Transdermal Buprenorphine Compared with Oral Opioid Medications in the Usual Care of Osteoarthritis Pain,” Patient, vol. 9, pp. 359–371, 2016, doi: 10.1007/s40271-016-0181-0.
[21] M. N. Pastore, Y. N. Kalia, M. Horstmann, and M. S. Roberts, “Transdermal patches: history, development and pharmacology,” Br J Pharmacol, vol. 172, no. 9, pp. 2179–2209, May 2015, doi: 10.1111/bph.13059.
[22] “Holling HE, McArdle B, Trotter WR (1944),” The James Lind Library, Jul. 12, 2013. https://www.jameslindlibrary.org/holling-he-mcardle-b-trotter-wr-1944/ (accessed Aug. 19, 2020).
[23] S. Sved, W. M. McLean, and I. J. McGilveray, “Influence of the method of application on pharmacokinetics of nitroglycerin from ointment in humans,” J Pharm Sci, vol. 70, no. 12, pp. 1368–1369, Dec. 1981, doi: 10.1002/jps.2600701220.
[24] D. A. Sica and R. Grubbs, “Transdermal clonidine: therapeutic considerations,” J Clin Hypertens (Greenwich), vol. 7, no. 9, pp. 558–562, Sep. 2005, doi: 10.1111/j.1524-6175.2005.04133.x.
[25] J. W. Goldzieher and R. E. Baker, “The percutaneous absorption of estradiol-17beta and progesterone,” J. Invest. Dermatol., vol. 35, pp. 215–218, Oct. 1960.
[26] C. for D. E. and Research, “Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book),” FDA, Aug. 2020, Accessed: Aug. 19, 2020. [Online]. Available: https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book.
[27] T. T. Nguyen, V. V. Giau, and T. K. Vo, “Current advances in transdermal delivery of drugs for Alzheimer’s disease,” Indian J Pharmacol, vol. 49, no. 2, pp. 145–154, 2017, doi: 10.4103/0253-7613.208143.
[28] A. S. Ham and R. W. Buckheit, “Current and emerging formulation strategies for the effective transdermal delivery of HIV inhibitors,” Ther Deliv, vol. 6, no. 2, pp. 217–229, Feb. 2015, doi: 10.4155/tde.14.110.
[29] R. L. Findling and S. Dinh, “Transdermal Therapy for Attention-Deficit Hyperactivity Disorder with the Methylphenidate Patch (MTS),” CNS Drugs, vol. 28, no. 3, pp. 217–228, 2014, doi: 10.1007/s40263-014-0141-y.
[30] M. Serpell, S. Tripathi, S. Scherzinger, S. Rojas-Farreras, A. Oksche, and M. Wilson, “Assessment of Transdermal Buprenorphine Patches for the Treatment of Chronic Pain in a UK Observational Study,” Patient, vol. 9, pp. 35–46, 2016, doi: 10.1007/s40271-015-0151-y.
[31] N. Al-Tawil, I. Odar-Cederlöf, A.-C. Berggren, H. E. Johnson, and J. Persson, “Pharmacokinetics of transdermal buprenorphine patch in the elderly,” Eur J Clin Pharmacol, vol. 69, no. 2, pp. 143–149, Feb. 2013, doi: 10.1007/s00228-012-1320-8.
[32] K. S. Paudel, M. Milewski, C. L. Swadley, N. K. Brogden, P. Ghosh, and A. L. Stinchcomb, “Challenges and opportunities in dermal/transdermal delivery,” Ther Deliv, vol. 1, no. 1, pp. 109–131, Jul. 2010, doi: 10.4155/tde.10.16.
[33] J. J. Berti and J. J. Lipsky, “Transcutaneous drug delivery: a practical review,” Mayo Clin. Proc., vol. 70, no. 6, pp. 581–586, Jun. 1995, doi: 10.4065/70.6.581.
[34] F. Blasi, F. Raddi, and M. Miravitlles, “Interactive Monitoring Service and COPD: Is it Possible to Reduce Nonadherence?,” COPD, vol. 12, no. 3, pp. 227–232, Jun. 2015, doi: 10.3109/15412555.2014.933796.
[35] J. D. Bos and M. M. Meinardi, “The 500 Dalton rule for the skin penetration of chemical compounds and drugs,” Exp. Dermatol., vol. 9, no. 3, pp. 165–169, Jun. 2000, doi: 10.1034/j.1600-0625.2000.009003165.x.
[36] A. P. Funke, C. Günther, R. H. Müller, and R. Lipp, “In-vitro release and transdermal fluxes of a highly lipophilic drug and of enhancers from matrix TDS,” J Control Release, vol. 82, no. 1, pp. 63–70, Jul. 2002, doi: 10.1016/s0168-3659(02)00105-0.
[37] M. H. Qvist, U. Hoeck, B. Kreilgaard, F. Madsen, and S. Frokjaer, “Release of chemical permeation enhancers from drug-in-adhesive transdermal patches,” Int J Pharm, vol. 231, no. 2, pp. 253–263, Jan. 2002, doi: 10.1016/s0378-5173(01)00893-6.
[38] S. Banerjee, P. Chattopadhyay, A. Ghosh, P. Datta, and V. Veer, “Aspect of adhesives in transdermal drug delivery systems,” International Journal of Adhesion and Adhesives, vol. 50, pp. 70–84, Apr. 2014, doi: 10.1016/j.ijadhadh.2014.01.001.
[39] R. J. Scheuplein and I. H. Blank, “Permeability of the skin,” vol. 51, p. 46, 1971.
[40] B. Bednarczyk-Cwynar, D. Partyka, and L. Zaprutko, “Simple amides of oleanolic acid as effective penetration enhancers,” PLoS ONE, vol. 10, no. 5, p. e0122857, 2015, doi: 10.1371/journal.pone.0122857.
[41] A. C. Williams and B. W. Barry, “The enhancement index concept applied to terpene penetration enhancers for human skin and model lipophilic (oestradiol) and hydrophilic (5-fluorouracil) drugs,” International Journal of Pharmaceutics, vol. 74, no. 2, pp. 157–168, Aug. 1991, doi: 10.1016/0378-5173(91)90232-D.
[42] R. B. Walker and E. W. Smith, “The role of percutaneous penetration enhancers,” Advanced Drug Delivery Reviews, vol. 18, no. 3, pp. 295–301, Feb. 1996, doi: 10.1016/0169-409X(95)00078-L.
[43] A. Eichner et al., “Influence of the penetration enhancer isopropyl myristate on stratum corneum lipid model membranes revealed by neutron diffraction and 2H NMR experiments,” Biochim Biophys Acta Biomembr, vol. 1859, no. 5, pp. 745–755, May 2017, doi: 10.1016/j.bbamem.2017.01.029.
[44] T. N. Engelbrecht, B. Demé, B. Dobner, and R. H. H. Neubert, “Study of the influence of the penetration enhancer isopropyl myristate on the nanostructure of stratum corneum lipid model membranes using neutron diffraction and deuterium labelling,” Skin Pharmacol Physiol, vol. 25, no. 4, pp. 200–207, 2012, doi: 10.1159/000338538.
[45] H. A. E. Benson, “Skin Structure, Function, and Permeation,” in Topical and Transdermal Drug Delivery, John Wiley & Sons, Ltd, 2012, pp. 1–22.
[46] D. G. Maillard-Salin, P. Bécourt, and G. Couarraze, “Physical evaluation of a new patch made of a progestomimetic in a silicone matrix,” Int J Pharm, vol. 199, no. 1, pp. 29–38, Apr. 2000, doi: 10.1016/s0378-5173(00)00357-4.
[47] N. Sadrieh, “Challenges in the Development of Transdermal Drug Delivery Systems,” FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology, Aug. 2009.
[48] T. Hikima and K. Tojo, “Binding of prednisolone and its ester prodrugs in the skin,” Pharm Res, vol. 14, no. 2, pp. 197–202, Feb. 1997, doi: 10.1023/a:1012052827872.
[49] J.-Y. Reginster, Y. Donazzolo, N. Brion, and R. Lins, “Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches,” null, vol. 3, no. 3, pp. 168–175, Jan. 2000, doi: 10.1080/13697130008500093.
[50] A. M. Kaunitz, D. Portman, C. L. Westhoff, D. R. Mishell, D. F. Archer, and M. Foegh, “New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study,” Contraception, vol. 91, no. 3, pp. 211–216, Mar. 2015, doi: 10.1016/j.contraception.2014.11.013.
[51] D. R. Friend, “Transdermal delivery of levonorgestrel,” Medicinal Research Reviews, vol. 11, no. 1, pp. 49–80, 1991, doi: https://doi.org/10.1002/med.2610110105.
[52] S. Logsdon, J. Richards, and H. A. Omar, “Long-Term Evaluation of the Use of the Transdermal Contraceptive Patch in Adolescents,” ScientificWorldJournal, vol. 4, pp. 512–516, Jul. 2004, doi: 10.1100/tsw.2004.107.
[53] D. R. Friend, S. J. Phillips, and J. R. Hill, “Cutaneous effects of transdermal levonorgestrel,” Food and Chemical Toxicology, vol. 29, no. 9, pp. 639–646, Jan. 1991, doi: 10.1016/0278-6915(91)90147-Y.
[54] L. Frank, “Prednisolone Topically and Systemically: A Clinical Evaluation in Selected Dermatoses: Preliminary Report,” AMA Arch Derm, vol. 72, no. 6, p. 547, Dec. 1955, doi: 10.1001/archderm.1955.03730360053005.
[55] S. L. Thornton and M. A. Darracq, “Patch Problems? Characteristics of Transdermal Drug Delivery System Exposures Reported to the National Poison Data System,” J. Med. Toxicol., vol. 16, no. 1, pp. 33–40, Jan. 2020, doi: 10.1007/s13181-019-00723-0.
[56] A. Isowaki, A. Ohtori, Y. Matsuo, and K. Tojo, “Drug delivery to the eye with a transdermal therapeutic system,” Biol Pharm Bull, vol. 26, no. 1, pp. 69–72, Jan. 2003, doi: 10.1248/bpb.26.69.
[57] C. Wu et al., “Self-Powered Iontophoretic Transdermal Drug Delivery System Driven and Regulated by Biomechanical Motions,” Advanced Functional Materials, vol. 30, no. 3, p. 1907378, 2020, doi: https://doi.org/10.1002/adfm.201907378.
[58] M. Azmana, S. Mahmood, A. R. Hilles, U. K. Mandal, K. A. Saeed Al-Japairai, and S. Raman, “Transdermal drug delivery system through polymeric microneedle: A recent update,” Journal of Drug Delivery Science and Technology, vol. 60, p. 101877, Dec. 2020, doi: 10.1016/j.jddst.2020.101877.
[59] M. H. Aboumanei and Ashgan. F. Mahmoud, “Design and development of a proniosomal transdermal drug delivery system of caffeine for management of migraine: In vitro characterization, 131I-radiolabeling and in vivo biodistribution studies,” Process Biochemistry, vol. 97, pp. 201–212, Oct. 2020, doi: 10.1016/j.procbio.2020.07.018.
[60] G. V. Radha, T. S. Rani, and B. Sarvani, “A review on proniosomal drug delivery system for targeted drug action,” Journal of Basic and Clinical Pharmacy, vol. 4, no. 2, May 2015, Accessed: Nov. 10, 2020. [Online]. Available: https://www.jbclinpharm.org/abstract/a-review-on-proniosomal-drug-delivery-system-for-targeted-drug-action-1390.html.
[61] E. B. Souto et al., “SLN and NLC for topical, dermal, and transdermal drug delivery,” Expert Opinion on Drug Delivery, vol. 17, no. 3, pp. 357–377, Mar. 2020, doi: 10.1080/17425247.2020.1727883.
[62] S. N. Shrotriya, N. S. Ranpise, and B. V. Vidhate, “Skin targeting of resveratrol utilizing solid lipid nanoparticle-engrossed gel for chemically induced irritant contact dermatitis,” Drug Deliv. and Transl. Res., vol. 7, no. 1, pp. 37–52, Feb. 2017, doi: 10.1007/s13346-016-0350-7.